

Canine malasseziosis: An overview

A. K. Daniel^{1*}

¹Department of Veterinary Clinical Medicine, Ethics and Jurisprudence, College of Veterinary and Animal Sciences, Pookode, Wayanad- 673 576, Kerala, India

Abstract

The present review describes the prevalence, etiology, pathogenesis, clinical manifestations, clinical pathology, diagnosis, treatment and zoonotic importance of *Malassezia* infections in dogs. *Malassezia* spp. are non-mycelial saprophytic lipophilic yeasts that belong to normal cutaneous or mucosal microbiota of many warm-blooded vertebrates. They may act as an opportunistic agent and plays a role in the development of *Malassezia* dermatitis and otitis externa in animals. Pathogenicity of *Malassezia* yeasts depends on the production of various virulence factors like proteases, lipases, phospholipases, lipoxygenases and other enzymes. Treatment of malasseziosis in dogs includes the use of topical therapy and systemic therapy. If predisposing factors cannot be controlled, recurrence is common, administration of routine topical therapy or pulse oral medications can be done. Polymerase Chain Reaction (PCR) is used as an effective diagnostic tool for the identification of *Malassezia* species. Sequencing is the most widely used method to understand the genetic diversity among *Malassezia* spp., including sequencing of the large subunit, internal transcribed spacer 1 region, the intergenic spacer 1 of ribosomal RNA and chitin synthase 2 gene.

Key words: Malasseziosis, Pathogenicity, Polymerase Chain Reaction, Sequencing

Highlights:

- Description of prevalence, etiology, pathogenesis, clinical manifestations, clinical pathology, diagnosis, treatment and zoonotic importance of *Malassezia* infections in dogs are described.
- Molecular techniques are considered an effective diagnostic tool for identifying many of the currently recognized *Malassezia* species.
- Identification and correction of predisposing factors are necessary to reduce the chance of recurrence of infection.

INTRODUCTION

Skin is the largest organ of the body, and it serves as a protective barrier between the animal's body and its environment. The skin of a dog represents 12% to 24% of its body weight (Moriello, 2016). *Malassezia* spp. are commensals of the normal cutaneous microflora of humans and animals. These yeasts may become opportunistic pathogens causing dermatitis (Figueredo *et al.*, 2012). *Malassezia* spp. was commonly isolated from the face, neck, legs, ears and digits of the affected animals (Kumar *et al.*, 2011). Dermatitis caused by *Malassezia pachydermatis* is one of the common skin mycosis in dogs and cats (Kano *et al.*, 2020). Bardshiri *et al.* (2014)

opined that the occurrence of *Malassezia pachydermatis* was more prevalent in adult dogs between one to eight years. The highest percentage of dogs with otitis associated with *Malassezia pachydermatis* was seen in the age group of one to three years (Girao *et al.*, 2006). Dog breeds like West Highland White Terriers, English Setters, Shih Tzus, Basset Hounds, American Cocker Spaniels, Boxers, Dachshunds, Poodles and Australian Silky Terriers were at increased risk of *Malassezia* dermatitis (Guillot and Bond, 2020). Kashif *et al.* (2016) stated that Saint Bernard and Cocker Spaniel having pendulous ears were more prone to *Malassezia* otitis than breeds having an erect ear, such as German Shepherd

*Corresponding Author, E mail: anjudaniel101969@gmail.com

and Russian breeds. Khosravi *et al.* (2016) reported a higher prevalence of *Malassezia* species in male dogs (57.6%) than in females (42.4%) with dermatitis. Nardoni *et al.* (2004) studied the occurrence of *Malassezia* yeasts in dogs of both sexes and observed a prevalence rate of 65.3% in males and 61% in females. Nichita and Marcu (2010) were of the view that malasseziosis occur most commonly as a secondary infection and tends to complicate other conditions like allergies, keratinization disorders, skin fold dermatitis, immunodeficiency and previous antibiotic administration. Morris (1999) reported that allergies like atopy, food allergy, flea allergy and contact allergy, keratinization disorders like seborrhea, bacterial skin diseases, endocrinopathies like hyperadrenocorticism, hypothyroidism and diabetes mellitus, metabolic diseases (zinc-responsive dermatosis and superficial necrolytic dermatitis) and cutaneous or internal neoplasia could predispose dogs to *Malassezia* dermatitis and otitis externa. Sihelska *et al.* (2017) isolated *Malassezia* yeasts from 76 dogs out of 300 dogs presented with skin lesions, otitis externa or inflammation of the anal sacs. Among them, 79 isolates were identified as *Malassezia pachydermatis*, four isolates were identified as *Malassezia furfur*, and only one isolate was identified as *Malassezia nana*. The pathogenesis of the genus *Malassezia* depends on the production of enzymes (including lipases, phospholipases and hydrolases) that could contribute to cutaneous inflammation (Lautert *et al.*, 2011). Petrokilidou *et al.* (2019) were of the view that the production of lipases by *Malassezia* yeasts plays a role in the invasion, colonization, persistence and proliferation within host tissues. Velegraki *et al.* (2015) reported that the zymogen proenzyme of the yeast cell wall might initiate damage to keratinocyte integrity through the activation of the complement system and thus lead to epidermal spongiosis, inflammation and pruritus. Cafarchia *et al.* (2007) suggested that the interactions between beta-endorphin and

phospholipase activity in *Malassezia pachydermatis* isolates induced pathogenicity and produced skin lesions in dogs.

Clinically, *Malassezia* dermatitis in canines was characterized by erythematous lesions and greasy exudation in skin folds and toe webs. In chronic cases, the major clinical signs included traumatic alopecia, hyperpigmentation, lichenification and prominent malodour (Bond, 2010). Bond *et al.* (2020) stated that the clinical presentations in dogs with *Malassezia* dermatitis were pruritus, erythema, hyperpigmentation, lichenification, malodour, traumatic alopecia, and paronychia and otitis externa. Santoro *et al.* (2015) were of the view that the correlation of opportunistic bacteria such as *Staphylococcus pseudintermedius* and fungi such as *Malassezia* spp. in dogs may induce clinical signs of atopic dermatitis. Nardoni *et al.* (2008) opined that the major clinical features of canine *Malassezia* dermatitis include diffuse, regional or localized alopecia, hyperpigmentation, lichenification, erythema, erythematous macules, oily skin and hair, and excessive scaling. Mircean *et al.* (2010) reported skin lesions such as alopecia, hyperpigmentation, scales, follicular pustules, erosions, papules, vesicles, epidermal collarette, nodules, etc. in dogs with *Malassezia* dermatitis. Maynard *et al.* (2011) indicated that the frequent clinical signs in *Malassezia* dermatitis were pruritus, erythema, secondary hair loss, excoriations, greasy seborrhoea, scaling, rancid fat odour and hyperpigmentation through a randomized controlled trial on sixty seven dogs. Nayak (2018) reported that the average values of haemoglobin (Hb), packed cell volume (PCV), and total erythrocyte count (TEC) were significantly lower in fungal dermatological conditions in dogs. Dhillon *et al.* (2020) reported normocytic, normochromic anaemia in a hypothyroid dog with recurrent dermatological affections. Ramesh *et al.* (2018) found the presence of moderate leukocytosis, neutrophilia and eosinophilia in dogs with malasseziosis associated with hypothyroidism. Hoskins (2005) remarked that dogs with

superficial necrolytic dermatitis were prone to secondary *Malassezia* and staphylococcal infections. He also reported increase in serum liver enzymes like ALP and ALT. An increase in the levels of Alkaline Phosphatase (ALP) and Alanine Aminotransferase (ALT) was noticed in a dog diagnosed with recurrent pyoderma associated with *Malassezia* and hyperadrenocorticism (Reddy and Kumari, 2011). Brar *et al.* (2017) noticed a significant decrease in values of total serum protein in atopic dogs (5.8 ± 0.14 g/dL) as compared to healthy dogs (6.7 ± 0.11 g/dL). A mild decrease in values of albumin and globulin was also observed in these atopic dogs. A significant increase in total protein and globulin values and a reduction of serum albumin values and A:G ratio were observed in dogs affected with mycotic dermatitis (Joshi, 2019).

Impression smears from the wet lesions (interdigital spaces, skin folds) and tape strip impression smears from the dry lesions (alopecia associated with scaling, crusting or lichenification) suggestive of *Malassezia* dermatitis were used for cytological examination of diagnosis (Mircean *et al.*, 2010). Reddy and Sivajyothi (2016) reported that methylene blue-stained tape impression smears from the dry lesions and glass slide impression smear from the wet lesions were used to detect the *Malassezia* organisms cytologically under the oil immersion objective. Omodo-Eluk *et al.* (2003) concluded that adhesive tape and dry swab sampling techniques in combination with the culture method could be used to detect *Malassezia* spp. from the skin of dogs. Bensignor *et al.* (2002) concluded that *Malassezia* yeasts were determined by cytology using the tape-strip technique more effectively. He also stated that on cytology, higher yeast counts were obtained on the pinna, followed by the umbilical area, axilla and perianal area. Scott *et al.* (1995) reported that a case could be considered positive for malasseziosis only if more than five organisms were detected microscopically in case of samples from skin and more than ten organisms in case of samples

from the ear canal at 40X magnification. Pinchbeck *et al.* (2002) stated that cytologically, at least one body site having a mean of ≥ 1 yeast organism per oil immersion field (OIF) during microscopic examination of 10 consecutive OIF with corneocytes was considered positive for malasseziosis. Nascente *et al.* (2015) opined that a clinical case of canine malasseziosis could be considered positive by giving scores like '+' for up to five cells per oil immersion field, '++' for six to ten cells per oil immersion field and '+++' for more than ten cells per oil immersion field. Satishkumar *et al.* (2008) reported that *Malassezia pachydermatis* was isolated from clinically affected dogs with seborrheic dermatitis and/or otitis externa on Sabouraud dextrose agar (SDA) with chloramphenicol at 37°C within 3-5 days. He also reported that colonies of *Malassezia pachydermatis* in Sabouraud dextrose agar were raised, doomed or high, convex and smooth with cream colour initially that later became dry, wrinkled and buff to orange beige. Saranya (2011) concluded that Sabouraud's dextrose agar with olive oil added as lipid supplement could be used as a standard culture medium for the identification of *Malassezia* yeasts. Karlapudi (2017) isolated *Malassezia pachydermatis* from lesions suggestive of otitis in dogs on Sabouraud dextrose agar with 0.05 per cent of chloramphenicol at 37°C for 48 hours and observed that colonies were first white or creamy, turning to dark tan to brown colour within five to seven days. Rathnapriya *et al.* (2016) suggested using Modified Dixon's agar as an ideal culture medium for the isolation of *Malassezia* yeasts. She also stated a higher isolation rate could be achieved on Modified Dixon's agar compared to Sabouraud dextrose agar with olive oil overlay. Marin *et al.* (2018) also isolated *Malassezia pachydermatis* on Modified Dixon's agar (MDA) at 37°C for five days. Polymerase chain reaction (PCR) is an effective diagnostic tool for the identification of *Malassezia* species. Genetic typing of *Malassezia* species isolated from a dog with or without otitis and seborrheic dermatitis was

done by applying the Random Amplified Polymorphic DNA (RAPD) PCR technique (Eidi *et al.*, 2011). Harju *et al.* (2004) suggested an inexpensive method for isolating yeast genomic DNA from lipid cultures or directly from colonies. In this, cell lysis was followed by chloroform extraction and precipitation of DNA with ethanol. Machado *et al.* (2011) suggested a method for yeast cell wall lysis with lyticase (200 IU) at 30°C for 30 min in dogs with *Malassezia dermatitis*. Rodriguez and Vaneechoutte (2019) also reported the most efficient yeast cell lysis with the use of lyticase lysis buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 1.2 M sorbitol and 10 mM β -mercaptoethanol) containing 2 U of lyticase/ μ L. According to Zia *et al.* (2015), a PCR-RFLP (Restriction Fragment Length Polymorphism) method targeted toward 26S rDNA and with a restriction enzyme, *Hin6I* (*CfoI*) enzyme was used to identify various *Malassezia* species. Ilahi *et al.* (2018) opined that matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry could be used as a new laboratory diagnostic tool for the rapid and accurate identification of *Malassezia* species. Few phenotypic tests are available to differentiate *Malassezia* species, and some of them may overlap. So, DNA sequencing or other techniques like mass spectrometry may be used for specific identification. Molecular techniques are significant in the accurate identification of many of the currently recognized *Malassezia* species. Particularly, sequencing of D1/D2 domain of the large subunit of the rRNA gene, ITS, IGS, CHS2 and β -tubulin genes or regions aids in the accurate identification of species and recognition of genotypes that may have relevance for host-adaptation and virulence. Multiplex PCR can be used for rapid and specific identification of *Malassezia* spp. from skin specimens (Bond *et al.*, 2020).

Treatment of malasseziosis in dogs includes the use of topical therapy and systemic therapy. For localized lesions, topical antifungal agents are usually used and are more effective in short-

coated animals. Topical prevention of *Malassezia dermatitis* in dogs can be achieved effectively using 2% chlorhexidine/ 2% miconazole or 3% chlorhexidine shampoo twice weekly, which may be considered the topical treatment of the first choice. In chronic or generalized cases, systemic therapy with azole antifungals can be done. Commonly used azole derivatives in the treatment of malasseziosis include triazoles (like itraconazole, fluconazole, voriconazole, posaconazole and ravuconazole) and imidazoles (miconazole and ketoconazole). Azoles impair ergosterol synthesis in the fungal cell membrane by inhibiting cytochrome P450 sterol C14 α -demethylation (Koch *et al.*, 2012). Cafarchia *et al.* (2012) documented the highest *in vitro* antifungal susceptibility of *Malassezia pachydermatis* to itraconazole, followed by ketoconazole and posaconazole. Pinchbeck *et al.* (2002) suggested that both once-daily administration and pulse therapy of itraconazole were efficient in the treatment of *Malassezia pachydermatis* dermatitis and otitis in dogs at 5 mg/kg body weight. Identification and correction of underlying predisposing factors are necessary to reduce the chance of recurrence of infection. If predisposing factors cannot be controlled, administration of routine topical therapy or pulse oral medications can be done (Scott *et al.*, 2001). Traditional ayurvedic medicine uses various plants to cure skin diseases and infections. Neem compounds appear to have antibacterial, antifungal, anti-inflammatory and immunomodulatory effects. Bioactive compounds from neem like nimbidin, gedunin, and sulphur-containing compounds such as cyclic trisulphide and tetrasulphide have antifungal activity. Mainly, the oil of seed kernels and neem leaf extracts possess antifungal action (Brahmachari, 2004). Salazar *et al.* (2015) reported that terpenoids in neem (*Azadirachta indica*) extracts (both the neem leaves and seed oil extracts) had either fungistatic or fungicidal power on several pathogenic fungi.

From a zoonotic perspective, Morris *et al.* (2005) suggested that *Malassezia*

pachydermatis could be classified as an emerging zoonotic pathogen, especially in immune-compromised individuals. Fan *et al.* (2006) reported a clinical case of *Malassezia pachydermatis*-induced skin infection in an immunocompetent dog owner. Marin *et al.* (2018) reported the ability of *Malassezia pachydermatis* to adapt to new hosts and its potential for zoonotic transmission. Chang *et al.* (1998) remarked that *Malassezia pachydermatis* is a zoonotic pathogen in low birth weight ill infants.

Conclusion

Malassezia yeasts are unique with their strict dependence on lipids, cellular ultrastructure and dominance as eukaryotic inhabitant on the skin of warm-blooded vertebrates. *Malassezia* populations impart a reservoir of yeasts that

might proliferate and induce an inflammatory response under the influence of various host predisposing factors. Molecular techniques are considered as the accurate identification for many of the currently recognized *Malassezia* species. Regular treatment is often required to minimize relapses if predisposing factors are not controlled. Topical treatments are preferred over systemic treatments for long-term therapy because of a lower risk of toxicity. To reduce the risk of zoonosis, good hand hygiene by individuals in contact with pet dogs and cats should be highlighted.

Conflict of interest: Authors have no conflict of interest in this study.

Author's contribution: AKD: Acquisition of data, analysis and designing of the manuscript.

REFERENCES

- Bardshiri B, Tavana M, Peighambarzadeh SZ and Abdolrahimi M, 2014. Occurrence of *Malassezia pachydermatis* in the external ear canals of dogs with and without otitis externa. *Walia J*, 30: 24-26
- Bensignor E, Jankowski F, Seewald W, Touati F, Deville M *et al.*, 2002. Comparison of two sampling techniques to assess quantity and distribution of *Malassezia* yeasts on the skin of Basset Hounds. *Vet Dermatol*, 13(5): 237-241, doi: 10.1046/j.1365-3164.2002.00308.x
- Bond R, 2010. Superficial veterinary mycoses. *Clin Dermatol*, 28(2): 226-236, doi: 10.1016/j.clindermatol.2009.12.012
- Bond R, Morris DO, Guillot J, Bensignor EJ, Robson D *et al.*, 2020. Biology, diagnosis and treatment of *Malassezia* dermatitis in dogs and cats: Clinical Consensus Guidelines of the World Association for Veterinary Dermatology. *Vet Dermatol*, 31(1): 27-e4, doi: 10.1111/vde.12809
- Brahmachari G, 2004. Neem - An omnipotent plant: A retrospection. *ChemBiochem*, 5(4): 408-421, doi: 10.1002/cbic.200300749
- Brar RK, Dhaliwal PS, Kumar A, Chhabra S and Uppal SK, 2017. Clinico-pathological studies on atopic dermatitis in dogs. *J Anim Res*, 7(3): 507-513, doi: 10.5958/2277-940X.2017.00075.4
- Cafarchia C, Dell'Aquila ME, Capelli G, Minoia P and Otranto D, 2007. Role of β -endorphin on phospholipase production in *Malassezia pachydermatis* in dogs: new insights into the pathogenesis of this yeast. *Med Mycol*, 45(1): 11-15, doi: 10.1080/13693780600962718
- Cafarchia C, Figueredo LA, Iatta R, Montagna MT and Otranto D, 2012. *In vitro* antifungal susceptibility of *Malassezia pachydermatis* from dogs with and without skin lesions. *Vet Microbiol*, 155(2-4): 395-398, doi: 10.1016/j.vetmic.2011.09.008
- Chang HJ, Miller HL, Watkins N, Arduino MJ, Ashford DA *et al.*, 1998. An epidemic of *Malassezia pachydermatis* in an intensive care nursery associated with colonization of health care workers' pet dogs. *N Engl J Med*, 338(11): 706-711, doi: 10.1056/NEJM199803123381102
- Dhillon KS, Kaur SJ and Pabby S, 2020. Clinical management of hypothyroidism associated with recurrent pododermatitis in an obese male Beagle dog. *J Ent Zool Stud*, 8(3): 86-88
- Eidi S, Khosravi AR, Jamshidi SH and Soltani M, 2011. Molecular characterization of *Malassezia* species isolated from dog with and without otitis and seborrhoeic dermatitis. *World J Zool*, 6(2): 134-141
- Fan YM, Huang WM, Li SF, Wu GF, Lai K *et al.*, 2006. Granulomatous skin infection caused by *Malassezia pachydermatis* in a dog owner. *Arch Dermatol*, 142: 1181-1184, doi: 10.1001/archderm.142.9.1181

- Figueredo LA, Cafarchia C, Desantis S and Otranto D, 2012. Biofilm formation of *Malassezia pachydermatis* from dogs. *Vet Microbiol*, 160(1-2): 126-131, doi: 10.1016/j.vetmic.2012.05.012
- Girao MD, Prado MR, Brilhante RSN, Cordeiro RA, Monteiro AJ *et al.*, 2006. *Malassezia pachydermatis* isolated from normal and diseased external ear canals in dogs: A comparative analysis. *Vet J*, 172(3): 544-548, doi: 10.1016/j.tvjl.2005.07.004
- Guillot J and Bond R, 2020. *Malassezia* yeasts in veterinary dermatology: An updated overview. *Front Cell Infect Microbiol*, 10: 79, doi: 10.3389/fcimb.2020.00079
- Harju S, Fedosyuk H and Peterson KR, 2004. Rapid isolation of yeast genomic DNA: Bust n' Grab. *BMC Biotechnol*, 4: 8, doi: 10.1186/1472-6750-4-8
- Hoskins JD, 2005. Liver disease in the geriatric patient. *Vet Clin: Small Anim Pract*, 35: 617-634
- Ilahi A, Hadrich I, Goudjil S, Kongolo G, Chazal C *et al.*, 2018. Molecular epidemiology of a *Malassezia pachydermatis* neonatal unit outbreak. *Med Mycol*, 56(1): 69-77, doi: 10.1093/mmy/myx022
- Joshi P, 2019. Clinico-therapeutic studies on canine mycotic dermatitis. MVS thesis, G.B. Pant University of Agriculture and Technology, Pantnagar, pp 99
- Kano R, Aramaki C, Murayama N, Mori Y, Yamagishi K *et al.*, 2020. High multi-azole-resistant *Malassezia pachydermatis* clinical isolates from canine *Malassezia* dermatitis. *Med Mycol*, 58(2): 197-200, doi: 10.1093/mmy/myz037
- Karlapudi SK, 2017. Diagnosis and management of *Malassezia* otitis in dogs. *Pharma Innov J*, 6(9): 36-38
- Kashif M, Rizwan M, Durrani AZ, Nasir A and Kim G, 2016. Therapeutic trials to evaluate the efficacy of topical clotrimazole and nystatin on clinical cases of otitis externa in dogs caused by *Malassezia pachydermatis* in district Lahore and its suburbs in Pakistan. *J Biomed Transl Res*, 17(2): 26-29, doi: 10.12729/jbtr.2016.17.2.026
- Khosravi AR, Shokri H and Fahimirad S, 2016. Efficacy of medicinal essential oils against pathogenic *Malassezia* sp. isolates. *J Mycol Med*, 26(1): 28-34, doi: 10.1016/j.mycmed.2015.10.012
- Koch SN, Torres SM and Plumb DC, 2012. Canine and Feline Dermatology Drug Handbook. John Wiley & Sons, Inc., USA, pp 446
- Kumar KS, Selvaraj P, Vairamuthu S, Nagarajan B, Nambi AP *et al.*, 2011. Survey of fungal isolates from canine mycotic dermatitis in Chennai. *Tamilnadu J Vet Anim Sci*, 7(1): 48-50
- Lautert C, Ferreiro L, Jesus FPK, Zanette RA, Mahl DL *et al.*, 2011. Enzymatic characterization of *Malassezia pachydermatis* isolates from dogs. *Afr J Microbiol Res*, 5(21): 2986-2990
- Moriello KA, 2016. Pyoderma in Dogs. In: Aiello, S.E. and Moses, M.A. (ed.), *The Merck Veterinary Manual*. 11th edn., Merck & Co, Inc, Kenilworth, NJ, USA, pp 3325
- Machado ML, Ferreiro L, Ferreira RR, Corbellini LG, Deville M *et al.*, 2011. *Malassezia* dermatitis in dogs in Brazil: diagnosis, evaluation of clinical signs and molecular identification. *Vet Dermatol*, 22(1): 46-52, doi: 10.1111/j.1365-3164.2010.00909.x
- Marin JCG, Rojas FB and Escobar AJG, 2018. Physiological and molecular characterization of *Malassezia pachydermatis* reveals no differences between canines and their owners. *Open J Vet Med*, 8(7): 87-105, doi: 10.4236/ojvm.2018.87010
- Maynard L, Reme CA and Viaud S, 2011. Comparison of two shampoos for the treatment of canine *Malassezia* dermatitis: A randomized controlled trial. *J Small Anim Pract*, 52(11): 566-572, doi: 10.1111/j.1748-5827.2011.01124.x
- Mircean V, Titilincu A, Mircean M and Magdas C, 2010. *Malassezia pachydermatis* infection in dogs: A retrospective of its epidemiology, clinical and cytological results in Cluj, Romania. *Sci Parasitol*, 11(3): 153-163
- Morris DO, 1999. *Malassezia* dermatitis and otitis. *Vet Clin North Am Small Anim Pract*, 29: 1303-1310, doi: 10.1016/s0195-5616(99)50128-9
- Morris DO, O'Shea K, Shofer FS and Rankin S, 2005. *Malassezia pachydermatis* carriage in dog owners. *Emerg Infect Dis*, 11(1): 83-88, doi: 10.3201/eid1101.040882
- Nardoni S, Corazza M and Mancianti F, 2008. Diagnostic and clinical features of animal *malasseziosis*. *Parassitologia*, 5(1-2): 81-83
- Nardoni S, Mancianti F, Corazza M and Rum A, 2004. Occurrence of *Malassezia* species in healthy and dermatologically diseased dogs. *Mycopathologia*, 157(4): 383-388, doi: 10.1023/b:myco.0000030416.36743.dd
- Nascente PS, Meinerz AR, Faria R, Nobre M, Escareno JJ *et al.*, 2015. *Malassezia pachydermatis* presence in canine external otitis and dermatopathies. *J Yeast Fungal Res*, 6(3): 25-30, doi: 10.5897/JYFR2015.0155
- Nayak S, 2018. Haematological and electrolyte profile of dogs suffering from chronic dermatitis. *MVSc*

- thesis, Orissa University of Agriculture and Technology, Bhubaneswar, pp 61
- Nichita I and Marcu A, 2010. The fungal microbiota isolated from cats and dogs. *Scient Pap: Anim Sci Biotechnol*, 43(1): 411-414
- Omodo-Eluk AJ, Baker KP and Fuller H, 2003. Comparison of two sampling techniques for the detection of *Malassezia pachydermatis* on the skin of dogs with chronic dermatitis. *Vet J*, 165(2): 119-124, doi: 10.1016/s1090-0233(02)00128-4
- Petrokilidou C, Pavlou E, Gaitanis G, Bassukas ID, Saridomichelakis MN *et al.*, 2019. The lipid profile of three *Malassezia* species assessed by Raman spectroscopy and discriminant analysis. *Mol Cell Probes*, 46: 101416, doi: 10.1016/j.mcp.2019.06.006
- Pinchbeck LR, Hillier A, Kowalski JJ and Kwochka KW, 2002. Comparison of pulse administration versus once daily administration of itraconazole for the treatment of *Malassezia pachydermatis* dermatitis and otitis in dogs. *J Am Vet Med Assoc*, 220(12): 1807-1812, doi: 10.2460/javma.2002.220.1807
- Ramesh S, Sokkalingam R, Subapriya S, Soundararajan C and Muthukrishnan S, 2018. Hypothyroidism in a dog- A Case Report. *Int J Curr Microbiol App Sci*, 7(12): 3686-3689, doi: 10.20546/ijemas.2018.712.417
- Rathnapriya N, UshaKrishnan K and Janaki C, 2016. Isolation of *Malassezia* yeast using Modified Dixon's Agar from Pityriasis versicolor lesions. *Indian J Basic Appl Med Res*, 5(3): 123-129
- Reddy BS and Sivajothi S, 2016. Recurrent *Malassezia* dermatitis due to hypothyroidism in a dog and its management. *Comp Clin Path*, 25(3): 531-533, doi: 10.1007/s00580-015-2218-5
- Reddy BS and Kumari KN, 2011. Recurrent pyoderma with *Malassezia* and hyperadrenocorticism in a dog. *Indian J Fld Vet*, 7(2): 44-45
- Rodriguez A and Vaneechoutte, M, 2019. Comparison of the efficiency of different cell lysis methods and different commercial methods for RNA extraction from *Candida albicans* stored in RNAlater. *BMC Microbiol*, 19(1): 94, doi: 10.1186/s12866-019-1473-z
- Salazar ODI, Sanchez HRA, Sanchez OF, Arteaga AM and Londono GLF, 2015. Antifungal activity of neem (*Azadirachta indica*: Meliaceae) extracts against dermatophytes. *Acta Biol Colomb*, 20(3): 201-207, doi: 10.15446/abc.v20n3.45225
- Santoro D, Marsella R, Pucheu Haston CM, Eisenschenk MN, Nuttall T *et al.*, 2015. Pathogenesis of canine atopic dermatitis: skin barrier and host-micro organism interaction. *Vet Dermatol*, 26(2): 84-e25, doi: 10.1111/vde.12197
- Saranya MG, 2011. Epidemiology and clinic-therapeutic studies of *Malassezia* dermatitis in dogs. MVSc thesis, Kerala Veterinary and Animal Sciences University, Pookode, pp 106
- Satishkumar K, Latha MS, Sai Prasanna J, Dhanalakshmi K and Sarma BJR, 2008. Cultural and electron microscopic studies of *Malassezia pachydermatis*. *Indian Vet J*, 85(4): 371-374
- Scott DW, Miller WH and Griffin CE, 1995. Fungal skin disease. In: Muller and Kirk's Small Animal Dermatology, 5th edn., WB Saunders Company, Philadelphia, PA, pp 329-391
- Scott DW, Miller WH and Griffin CE, 2001. *Malassezia* dermatitis. In: Muller and Kirk's Small Animal Dermatology, 6th Edn, WB, Saunders, Philadelphia, pp 363-74
- Sihelska Z, Conkova E, Vaczi P, Harcarova M and Bohmova E, 2017. Occurrence of *Malassezia* yeasts in dermatologically diseased dogs. *Folia Vet*, 61(2): 17-21, doi: 10.1515/fv-2017-0013
- Velegaki A, Cafarchia C, Gaitanis G, Iatta R and Boekhout T, 2015. *Malassezia* infections in humans and animals: pathophysiology, detection, and treatment. *PLoS Pathogens*, 11(1): e1004523, doi: 10.1371/journal.ppat.1004523
- Zia M, Mirhendi H and Toghyani M, 2015. Detection and identification of *Malassezia* species in domestic animals and aquatic birds by PCR-RFLP. *Iranian J Vet Res*, 16: 36